PC
AZN icon

PointState Capital’s AstraZeneca AZN Stock Holding History

PointState Capital’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-686,500
Closed -$80M – 76
2021
Q4 		$80M Sell
686,500
-127,250
-16% -$15M 1.33% 24
2021
Q3 		$97.7M Buy
+813,750
New +$94.7M 1.63% 19

Other funds holding AZN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
GQG Partners
GQG Partners Ft. Lauderdale, Florida $63.1B AUM 23.07% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CIBC Private Wealth Group
CIBC Private Wealth Group Atlanta, Georgia $59.2B AUM 20.62% 1-Year Est. Return

PointState Capital's AZN Position: Q3 2022 in Review

PointState Capital sold out of AstraZeneca (AZN) in Q3 2022, closing a stake of 33,675 shares — an estimated $4.45M sold.

PointState Capital first reported a position in AZN in Q1 2018 and held it in 6 quarters. The position peaked at $49.4M in Q3 2021. 966 funds tracked by Wall St. Rank hold AZN as of Q3 2022.

  • PointState Capital reported no remaining AstraZeneca position as of Q3 2022 after selling out during the quarter.
  • PointState Capital sold 33,675 AstraZeneca shares in Q3 2022, an estimated $4.45M.
  • PointState Capital first reported a position in AstraZeneca in Q1 2018 and held it in 6 quarters.
  • PointState Capital's AstraZeneca position peaked at $49.4M in Q3 2021.
  • 966 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2022.

Based on PointState Capital's 13F filing for Q3 2022, filed 10 Nov 2022.